IP Library Granted Patent US 11,690,902
Granted Patent B2
US 11,690,902 · App. 16/982,141 · Granted Jul 4, 2023

Patent

Inventors: Mark C. Poznansky (Newton, MA); Ann Elizabeth Sluder (Bedford, MA); Timothy Alan Brauns (Roslindale, MA); Anne Searls De Groot (Providence, RI); Leonard Jeffrey Moise (Providence, RI); Anja Garritsen (Oss, NL); Anja Scholzen (Nijmegen, NL)
Assignees: The General Hospital Corporation; EpiVax, Inc.; Innatoss Laboratories B.V.
A61K39/0208A61K39/0233A61K39/04C07K14/195A61K2039/53A61K2039/6043A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,690,902
App. No.
16/982,141
Granted
Jul 4, 2023
Kind
B2
Abstract

Compositions and methods for inducing a protective immune response against Coxiella burnetii , to reduce a subject's risk of developing Q fever.

Claims (13)

1. A composition comprising one or more isolated nucleic acids encoding a polypeptide comprising three or more epitope peptides of Coxiella burnetti source antigens, wherein the three or more epitope peptides are selected from the group consisting of p4, p12, p14, p15, p17, p18, p20, p21, p22, p26, p27, p30, p37, p38, p42, p43, p45, and p48, each of which consists of SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO:18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, and SEQ ID NO: 48 respectively, optionally with linkers therebetween, and a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein the polypeptide further comprises one or more of p2, p6, p19, p23, p24, p31, p46, p47, and p50 epitope peptides, each of which consists of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 31, SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 50 respectively.

3. The composition of claim 2 , wherein the polypeptide further comprises one or more of pl, p3, p5, p7, p8, p10, p13, p16, p25, p28, p29, p32, p33, p36, p39, p41, and p44, each of which consists of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 36, SEQ ID NO: 39, SEQ ID NO: 41, and SEQ ID NO: 44 respectively.

4. The composition of claim 1 , wherein the one or more nucleic acids are in a viral vector.

5. The composition of claim 1 , wherein the one or more nucleic acids are in an adenoviral vector or a vaccinia viral vector.

6. The composition of claim 1 , wherein the one or more nucleic acid a in an RNA transcript.

7. The composition of claim 1 , wherein the polypeptide is a fusion protein.

8. The composition of claim 1 , wherein the three or more epitope peptides are present as concatemers.

9. The composition of claim 8 , wherein the polypeptide comprising the concatemers is fused to Mycobacterium tuberculosis Hsp70.

10. The composition of claim 1 , further comprising an adjuvant, an antibiotic, or both.

11. The composition of claim 1 , wherein the polypeptide is a concatenated polypeptide comprising the amino acid sequence of SEQ ID NO: 57.

12. The composition of claim 2 , wherein the polypeptide is a concatenated polypeptide comprising the amino acid sequence of SEQ ID NO: 58.

13. The composition of claim 3 , wherein the polypeptide is a concatenated polypeptide comprising the amino acid sequence of SEQ ID NO: 59.

Assignments (6)
SECURITY INTEREST Recorded Jun 30, 2026
From: EPIVAX, INC.; EPV INTERMEDIATE HOLDINGS, LLC
To: FIFTH THIRD BANK, N.A.
Reel/Frame 075141/0047 →
SECURITY INTEREST Recorded Mar 31, 2026
From: EPIVAX, INC.
To: ESCALATE CAPITAL V, LP
Reel/Frame 074239/0943 →
CONFIRMATORY LICENSE Recorded Oct 11, 2023
From: MCLEAN HOSPITAL
To: DEFENSE THREAT REDUCTION AGENCY, US DOD
Reel/Frame 065212/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2021
From: POZNANSKY, MARK C.; SLUDER, ANN E.; BRAUNS, TIMOTHY A.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 056172/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2021
From: GARRITSEN, ANJA; SCHOLZEN, ANJA
To: INNATOSS LABORATORIES B.V.
Reel/Frame 055645/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2021
From: DE GROOT, ANNE SEARLS; MOISE, LEONARD JEFFREY
To: EPIVAX, INC.
Reel/Frame 055662/0521 →
Continuity (2)
Provisional Application 62647156 · Mar 23, 2018
Related Publication 20210113679A1 · Apr 22, 2021